Mantle cell lymphoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 20
• BTK 17
• CD20 8
• TP53 2
• BCL-2 5
• PI3K 0
• CD22 3
• MYC 0
• PD-1 2
• CXCR4 0
• EGFR 0
• PD-L1 1
• PRMT5 0
• ALK 0
• CD47 0
• JAK 0
• STAT3 0
• AKT 0
• ATM 0
• BRCA1 1
• BRCA2 1
• BRD4 0
• CCR5 0
• CD40 0
• FLT3 0
• GPX4 0
• HDAC 0
• HSP90 0
• KMT2A 0
• MET 0
• mTOR 0

24 of 33+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

  NCT06256484· Atara Biotherapeutics· Updated 11 Mar 2026

  “Financial reasons”Registry text, quoted unchanged. Source

• Terminated

  Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

  NCT06343376· Roswell Park Cancer Institute· Updated 3 Aug 2025

  “Manufacturing issues”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

  NCT06026319· Marcela V. Maus, M.D.,Ph.D.· Source

• A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

  NCT06045910· Cancer Research UK· Source

• ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

  NCT04049513· Malaghan Institute of Medical Research· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• Gene Expression Profiling 6
• Proteomics 1
• Flow Cytometry 6
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 7
• Magnetic Resonance Imaging 1
• Machine Learning 2
• Deep Learning 1
• Cohort Studies 2

• Minimal residual disease guided treatment approaches in non-Hodgkin lymphoma-Where we are and where we're headed.

  Semin Hematol, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.